Tuesday, 17 November 2026 Every SEC filing alert, by company
ALFA USA Filings Every alert, straight from SEC EDGAR
News
Earnings Call

Phibro Animal Health Earnings Call: Key Takeaways

Phibro delivered 6% revenue growth and 11% net income growth in Q1, maintaining FY2027 guidance despite margin pressure in animal health and regulatory delays in Brazil.

Full earnings call on the Alfa Finder USA YouTube channel · Open on YouTube ↗
Highlights
Revenue GrowthAnimal Health 3%, Mineral Nutrition 17%, Performance Products 16% growth.
Mgmt ConfidenceCautiously optimistic; maintained guidance despite Q1 beat due to expense timing.
Demand VisibilityStrong demand in MFA North America/Asia; lower poultry demand in North America.
Margin TrendsAdjusted EBITDA grew 4%; Animal Health EBITDA down $1M on SG&A.
Op. LeverageHigher SG&A offset gross profit improvements; corporate expenses decreased $0.6M.
Pricing PowerIncreased average selling prices for zinc oxide, copper, and trace minerals.
Vol vs PriceGrowth driven by both increased demand and higher average selling prices.
Segment GrowthMineral Nutrition outperformed at 17%; Animal Health lagged at 3%.
New ClientsTransition of Tier 3 markets (Canada, Europe) from Zoetis back to Phibro.
Capex & Debt$64M CapEx; $740M total debt; net leverage ratio 2.6 times.
Regulatory$5.2M sales decrease in Brazil due to Virginia Myson regulatory developments.
CommentaryFocus on debt flexibility and returns to shareholders while integrating Zoetis portfolio.

Growth

Consolidated sales rose 6% to $386.8M; Mineral Nutrition grew 17%, Performance Products 16%.

Outlook

FY2027 guidance: Revenue $1.55B-$1.6B (4% growth), Adjusted Net Income $140M-$147M (9% growth).

Risks

Management pivoted on EBITDA guidance raise, citing shifted expenses and Brazil regulatory delays.

Source

The company's earnings call, NASDAQ: PAHC, and its 8-K filed with the SEC. Summary written with AI assistance from the call.

Read the 8-K ↗

Phibro Animal Health Corp: key numbers

Share price
$35.02Close, Nov 16
Sector
Life Sciences
Industry
Pharmaceutical PreparationsSIC 2834

Today's reference numbers, updated daily. Not a valuation or a recommendation.

More from Phibro Animal Health Corp

All →
4:33 PM ET 8-K
Financial Results

Phibro Animal Health Financial Results

Phibro Animal Health reported Q1 2027 net sales of $386.8 million, a 6% increase year-over-year, driven by growth in Mineral Nutrition and Performance Products. The company maintained its full-year fiscal 2027 guidance despite regulatory headwinds for virginiamycin in Brazil. Additionally, shareholders ratified the election of three Class I directors and the appointment of PwC as auditors at the annual meeting.

Term
Q1 2027

“First quarter results exceeded our expectations and grew on top of a strong first quarter last year. The outperformance was led largely by a strong start to the year in Mineral Nutrition and Performance Products while our core Animal Health business delivered sales in line with our plan and Adjusted EBITDA ahead of plan, including the benefit of certain costs that shifted into the second quarter.”

Dani Bendheim, President and Chief Executive Officer

“Improving working capital and cash conversion is a top priority, and we are committed to delivering meaningful progress during fiscal 2027.”

Dani Bendheim, President and Chief Executive Officer
4:17 PM ET 10-Q
Financial Results ▶ Call

Phibro Animal Health Q1 2026 Results: Net Income $29.5M, Up 11.3% YoY

Phibro Animal Health Corp reported net sales of $386.8 million for the quarter ended September 30, 2026, a 6% increase compared to the prior year. Net income rose to $29.5 million ($0.72 per diluted share) from $26.5 million, driven by higher sales volume and improved foreign currency impacts despite an increase in selling, general, and administrative expenses.

Key figure
Net income $29.5M · +11.3% YoY
4:16 PM ET 8-K
Dividend

Phibro Animal Health Dividend

Phibro Animal Health Corporation declared a quarterly cash dividend of $0.12 per share on its Class A and Class B common stock. The dividend is payable on December 16, 2026, to stockholders of record as of November 25, 2026.

Get Alerts

Get ALFA Finder alerts first

Real-time SEC filing alerts for US stocks are launching soon. Leave your details and we'll tell you the moment they go live.